Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

Biogen (BIIB) guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected fourth-quarter results.

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

Sudbury artist Brian Nori has a story – one that takes the listener from his diagnosis of multiple sclerosis to the Amazon to his creative hub in the heart of downtown Sudbury. His journey is one of ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Researchers suggest the persistent inflammation from obesity may enhance the detrimental effects of intermittent or sustained ...

After a multiple sclerosis diagnosis, travel became nearly impossible for Selma Blair. At California’s iconic — and accessible — Rosewood Miramar Beach, the actor shares her advice on getting back out ...

Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...